2 Minutes with Joey - MRK Stock News

Two minutes with Joey on Merck (MRK) - a quick daily recap of what the stock did today and why, in plain English. Information and entertainment only, not financial advice.

2 Minutes with Joey - MRK Stock News is a general podcast hosted by Unknown Host, with 0 episodes on record and a Required Pod Score of 80. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.

Unknown Host hosts 2 Minutes with Joey - MRK Stock News, a general show with 0 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  2 Minutes with Joey - MRK Stock News

  MRK Today - Aug 06: Mixed Reactions to Guidance

  Aug 6, 20262 minS0

  Hey there! It’s Joey here, your friendly neighborhood investor, and I’m breaking down what went down with Merck today. So, Merck (MRK) had a bit of a mixed bag today, closing down just about 0.18%. Not a huge drop, but still, it got a bit of a nudge into the red.<br /><br />So, here’s the scoop. Merck reported its earnings, and while they beat quarterly estimates, they also cut guidance for the year. That’s always a tricky combo, right? Investors seemed to hit the sell button pretty quickly, even though there were some bright spots, like strong p...

  ListenShow Notes
• 

  2 Minutes with Joey - MRK Stock News

  MRK Today - Aug 05: Oncology Strength Shines Bright

  Aug 5, 20261 minS0

  Hey there! It’s Joey here, your friendly investor buddy, breaking down today’s market moves. Today, we’re talking about Merck, and guess what? It was a green day! The stock climbed up about 2.14%. Nice little gain, right?<br /><br />So, what went down? Merck's stock had a solid day, and it’s all about their oncology products. They absolutely crushed forecasts with some of their cancer treatments. I mean, when you blow past what everyone expected, that’ll definitely get the attention of Wall Street. While they did cut earnings guidance a bit, investors mostly shrugged that off. They were...

  ListenShow Notes
• 

  2 Minutes with Joey - MRK Stock News

  MRK Today - Aug 04: Oncology Strength Shines

  Aug 4, 20262 minS0

  Hey there! It's Joey, your friendly neighborhood investor, breaking down the day for you. Today, we’re talking about Merck, and it was a green day for them, up about three-quarters of a percent. Not a huge jump, but hey, green is always good, right?<br /><br />So, what went down? Merck's stock had a little bounce today, and honestly, a lot of that had to do with how Wall Street is seeing things. They just reported their Q2 earnings, and even though they had to cut their earnings guidance, people are still digging what they’re doing in oncology. That...

  ListenShow Notes
• 

  2 Minutes with Joey - MRK Stock News

  MRK Today - Aug 03: Earnings Buzz and HIV Updates

  Aug 3, 20262 minS0

  Hey there! It’s Joey, your friendly neighborhood investor, here to break down what went down with Merck today. So, Merck (MRK) had a bit of a rough ride, finishing the day in the red, down about 2%. <br /><br />Now, let’s talk about what happened. The stock got smoked, and honestly, it’s been a bit of a slow bleed lately. People were looking at the upcoming Q2 earnings report, and it seems like there was some tension in the air. You know how it goes—investors get a little jittery when earnings are around the corner. <br /><br />But that...

  ListenShow Notes
• 

  2 Minutes with Joey - MRK Stock News

  MRK Today - Aug 02: HIV Pill Licensing Plans

  Aug 2, 20261 minS0

  Hey there! It's Joey, your friendly neighborhood investor, here to break down what went down with Merck today. So, we're talking about MRK, and it was a pretty chill day, barely moving up just a little, like 0.33%. <br /><br />So, what happened? Merck's stock basically just hung out today. It didn’t get smoked or anything wild like that. Instead, it just sat there, trading in a pretty narrow range. Nothing too crazy, right? <br /><br />Now, why did it stay so steady? Well, there’s a couple of reasons floating around. First off, some folks are saying Merck looks belo...

  ListenShow Notes

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.